Bispecifics Move Into Frontline and Bridging Roles: What the ASH 2026 Program Shows

Titles in the lymphoma and myeloma sessions point to bispecific antibodies being studied in earlier settings and in combination with cellular therapy.

• Abstract 81 (Oral, 10:00–10:15 AM): “Glory interim analysis: A response-adapted glofitamab-based frontline strategy for older unfit or frail patients with DLBCL” (Torka).
• Abstract 84 (Oral, 10:45–11:00 AM): Glofitamab + polatuzumab vedotin as bridging therapy before CD19 CAR T, the UK PORTAL trial (Kuhnl; NCT06071871).
• Abstract 166 (Oral): Rituximab + epcoritamab as first-line therapy for high-tumor-burden follicular lymphoma (Merryman; NCT05783609).
• Abstract 167 (Oral): Epcoritamab-lenalidomide in treatment-naïve follicular lymphoma (Thiruvengadam).
• Abstract 271 (Oral, 2:00–2:15 PM): Post-CAR-T consolidation with fixed-duration elranatamab, the EPIC trial (Puliafito; NCT06138275).

Session 629 (Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies) is the one to watch for the lymphoma entries.